Investor Report – A Quick Overview for NTRA Investors

Natera logged a -1.7% change during today's morning session, and is now trading at a price of $62.8 per share. The S&P 500 index moved -0.0%. NTRA's trading volume is 67,965 compared to the stock's average volume of 1,352,738.

Natera trades -15.6% away from its average analyst target price of $74.41 per share. The 17 analysts following the stock have set target prices ranging from $37.0 to $117.0, and on average have given Natera a rating of buy.

Anyone interested in buying NTRA should be aware of the facts below:

  • Natera has moved 56.8% over the last year, and the S&P 500 logged a change of 20.1%

  • Based on its trailing earnings per share of -4.51, Natera has a trailing 12 month Price to Earnings (P/E) ratio of -13.9 while the S&P 500 average is 15.97

  • NTRA has a forward P/E ratio of -23.8 based on its forward 12 month price to earnings (EPS) of $-2.64 per share

  • Its Price to Book (P/B) ratio is 9.52 compared to its sector average of 4.08

  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide.

  • Based in Austin, the company has 2,958 full time employees and a market cap of $7.55 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.